Molecular Biology Reports

, Volume 37, Issue 3, pp 1269–1277 | Cite as

Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination

  • Ercument Cengiz
  • Burcak Karaca
  • Yuksel Kucukzeybek
  • Gurbuz Gorumlu
  • Mustafa K. Gul
  • Cigdem Erten
  • Harika Atmaca
  • Selim Uzunoglu
  • Bulent Karabulut
  • Ulus A. Sanli
  • Ruchan Uslu


Drug resistance is a significant challenge of daily oncology practice. Docetaxel and gossypol both have antitumoral activity in hormone-refractory prostate cancer (HRPC). Our results revealed that docetaxel and gossypol were synergistically cytotoxic and apoptotic in PC-3 cells in a dose- and time-dependent manner. We further investigated the expression profiles of genes involved in drug resistance and metabolism with a Human Cancer Drug Resistance and Metabolism PCR Array® (SuperArray). Six of the 84 genes that are known to regulate drug resistance, metabolism, cell cycle, DNA repair and oncogenesis were downregulated ≥3-fold change by the combination treatment. These results may be important in devising mechanism-based and targeted therapeutic strategies for prostate cancer, especially in devising combination therapy for drug resistant prostate cancers.


Docetaxel Gossypol PCR array Drug resistance PC-3 


  1. 1.
    Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B (1999) Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory cancer: a Hoosier Oncology Group and Fox Chase Network Phase III Trial. J Clin Oncol 17:3160PubMedGoogle Scholar
  2. 2.
    Pienta KJ, Naik H, Lehr JE (1996) Effect of estramustine, etoposide, and Taxol on prostate cancer cell growth in vitro and in vivo. Urology 48:164. doi: 10.1016/S0090-4295(96)00109-4 CrossRefPubMedGoogle Scholar
  3. 3.
    Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756PubMedGoogle Scholar
  4. 4.
    Shustik C, Dalton W, Gros P (1995) P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol Aspects Med 16:1. doi: 10.1016/0098-2997(94)00040-A CrossRefPubMedGoogle Scholar
  5. 5.
    Friesen C, Herr I, Krammer PH, Debatin KM (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2:574. doi: 10.1038/nm0596-574 CrossRefPubMedGoogle Scholar
  6. 6.
    Futscher BW, Foley NE, Gleason-Guzman MC, Meltzer PS, Sullivan DM, Dalton WS (1996) Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int J Cancer 66:520. doi: 10.1002/(SICI)1097-0215(19960516)66:4<520::AID-IJC16>3.0.CO;2-B CrossRefPubMedGoogle Scholar
  7. 7.
    Kubo H, Sumizawa T, Koga K, Nishiyama K, Takebayashi Y, Chuman Y, Furukawa T, Akiyama S, Ohi Y (1996) Expression of the multidrug resistance-associated protein (MRP) gene in urothelial carcinomas. Int J Cancer 69:488. doi: 10.1002/(SICI)1097-0215(19961220)69:6<488::AID-IJC13>3.0.CO;2-Y CrossRefPubMedGoogle Scholar
  8. 8.
    List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS (1996) Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87:2464PubMedGoogle Scholar
  9. 9.
    Beer TM, El Geneidi M, Eilers KM (2003) Docetaxel (taxotere) in the treatment of prostate cancer. Expert Rev Anticancer Ther 3:261–268. doi: 10.1586/14737140.3.3.261 CrossRefPubMedGoogle Scholar
  10. 10.
    Hong WK (2002) The current status of docetaxel in solid tumors. An M.D.Anderson Cancer Center Review. Oncology (Huntingt) 16:9–15Google Scholar
  11. 11.
    Li Y, Li X, Hussain M, Sarkar FH (2004) Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray. Neoplasia 6:158–167. doi: 10.1593/neo.03391 CrossRefPubMedGoogle Scholar
  12. 12.
    Petrylak DP, Tangen CM, Hussain MH (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520. doi: 10.1056/NEJMoa041318 CrossRefPubMedGoogle Scholar
  13. 13.
    Sun LC, Luo J, Mackey LV, Fuselier JA, Coy DH (2007) A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3 K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. Cancer Lett 246(1–2):157–166. doi: 10.1016/j.canlet.2006.02.016 CrossRefPubMedGoogle Scholar
  14. 14.
    Huang YW, Wang LS, Chang HL, Ye W, Dowd MK, Wan PJ, Lin YC (2006) Molecular mechanisms of (−)-gossypol-induced apoptosis in human prostate cancer cells. Anticancer Res 26:1925–1933PubMedGoogle Scholar
  15. 15.
    Xu L, Yang D, Wang S, Tang W, Liu M, Davis M, Chen J, Rae JM, Lawrence T, Lippman ME (2005) (−)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther 4:197–205PubMedCrossRefGoogle Scholar
  16. 16.
    Zhang M, Hongpeng L, Zhenkun T et al (2007) Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspase-dependent and caspase-independent cell death pathways. Life Sci 80:767. doi: 10.1016/j.lfs.2006.11.004 CrossRefPubMedGoogle Scholar
  17. 17.
    Mohammmad RM, Wangs S, Wu X et al (2005) Nonpeptidic small molecule inhibitor of Bcl-2 and Bcl-XL, (−) Gossypol, enhances biological effect of genistein against BxPC-3 human pancraetic cancer cell line. Pancreas 31:317. doi: 10.1097/01.mpa.0000179731.46210.01 CrossRefGoogle Scholar
  18. 18.
    Skjoth IH, Issinger OG (2006) Profiling of signaling molecules in four different human prostate carcinoma cell lines before and after induction of apoptosis. Int J Oncol 28:217PubMedGoogle Scholar
  19. 19.
    Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55. doi: 10.1016/0065-2571(84)90007-4 CrossRefPubMedGoogle Scholar
  20. 20.
    Hamilton A, Muggia F (2001) Estramustine potentiates taxane in prostate and refractory breast cancers. Oncology (Huntingt) 15:40–43Google Scholar
  21. 21.
    Kreis W, Budman D (1999) Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer. Semin Oncol 26:34–38PubMedGoogle Scholar
  22. 22.
    Fu M, Wang C, Li Z, Sakamaki T, Pestell RG (2004) Mainreview: cyclin D1: normal and abnormal functions. Endocrinology 145:5439–5447. doi: 10.1210/en.2004-0959 CrossRefPubMedGoogle Scholar
  23. 23.
    Pett WJ, Dragnev KH, Dmitrovsky E (2003) Cyclin D1 as a target for chemoprevention. Lung Cancer 41:155–161CrossRefGoogle Scholar
  24. 24.
    Fan S, Wang JA, Yuan R, Ma YX, Meng Q, Erdos MR, Brody LC, Goldberg ID, Rosen EM (1998) BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene 16:3069–3082. doi: 10.1038/sj.onc.1202116 CrossRefPubMedGoogle Scholar
  25. 25.
    Domingo-Domenech J, Fernandez PL, Fiella X, Martinez-Fernandez A, Molina R, Fernandez E, Alcaraz A, Codony J, Gascon P, Mellado B (2008) Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol 19:269–275. doi: 10.1093/annonc/mdm490 CrossRefPubMedGoogle Scholar
  26. 26.
    Signoretti S, Montironi R, Manola J (2000) Her-2 neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92:1918–1925. doi: 10.1093/jnci/92.23.1918 CrossRefPubMedGoogle Scholar
  27. 27.
    Shi Y, Brands FH, Chatterjee S (2001) Her2/neu expression in prostate cancer:high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 166:1514–1519. doi: 10.1016/S0022-5347(05)65822-3 CrossRefPubMedGoogle Scholar
  28. 28.
    Edwards J, Traynor P, Munro AF (2006) The role HER1-HER4 and EGFRvlll in hormone-refractory prostate cancer. Clin Cancer Res 12:123–130. doi: 10.1158/1078-0432.CCR-05-1445 CrossRefPubMedGoogle Scholar
  29. 29.
    Hernes E, Fossa SD, Berner A (2004) Expression of the epidermal growth factor family in prostate cancer carcinoma before and during androgen-independence. Br J Cancer 90:449–454CrossRefPubMedGoogle Scholar
  30. 30.
    Krynetski E, Evans WE (2003) Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 22:7403–7413CrossRefPubMedGoogle Scholar
  31. 31.
    Meng Y, Tang W, Dai Y, Wu X, Liu M, Ji Q, Ji M, Pienta K, Lawrence T, Xu L (2008) Natural BH3 mimetic (−)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 7:2192–2202. doi: 10.1158/1535-7163.MCT-08-0333 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Ercument Cengiz
    • 1
  • Burcak Karaca
    • 1
  • Yuksel Kucukzeybek
    • 1
  • Gurbuz Gorumlu
    • 1
  • Mustafa K. Gul
    • 1
  • Cigdem Erten
    • 1
  • Harika Atmaca
    • 2
  • Selim Uzunoglu
    • 2
  • Bulent Karabulut
    • 1
  • Ulus A. Sanli
    • 1
  • Ruchan Uslu
    • 1
  1. 1.Division of Medical Oncology, Tulay Aktas Oncology Hospital, School of MedicineEge UniversityBornovaTurkey
  2. 2.Section of Molecular Biology, Department of Biology, Faculty of Science and ArtsCelal Bayar UniversityMuradiyeTurkey

Personalised recommendations